Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

NCT05714839 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05714839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05714839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 14, 2023
Completion date
August 3, 2028
Enrollment
123 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma